Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

Abstract

Background: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and intensified chemoradiotherapy. All previous studies assessing the clinical importance of extent of resection have not accounted for molecular subgroup. We analysed the prognostic value of extent of resection in a subgroup-specific manner.; Methods: We retrospectively identified patients who had a histological diagnosis of medulloblastoma and complete data about extent of resection and survival from centres participating in the Medulloblastoma Advanced Genomics International Consortium. We collected from resections done between April, 1997, and February, 2013, at 35 international institutions. We established medulloblastoma subgroup affiliation by gene expression profiling on frozen or formalin-fixed paraffin-embedded tissues. We classified extent of resection on the basis of postoperative imaging as gross total resection (no residual tumour), near-total resection (<1·5 cm(2) tumour remaining), or sub-total resection (≥1·5 cm(2) tumour remaining). We did multivariable analyses of overall survival and progression-free survival using the variables molecular subgroup (WNT, SHH, group 4, and group 3), age (<3 vs ≥3 years old), metastatic status (metastases vs no metastases), geographical location of therapy (North America/Australia vs rest of the world), receipt of chemotherapy (yes vs no) and receipt of craniospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation). The primary analysis outcome was the effect of extent of resection by molecular subgroup and the effects of other clinical variables on overall and progression-free survival.; Findings: We included 787 patients with medulloblastoma (86 with WNT tumours, 242 with SHH tumours, 163 with group 3 tumours, and 296 with group 4 tumours) in our multivariable Cox models of progression-free and overall survival. We found that the prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. We identified a progression-free survival benefit for gross total resection over sub-total resection (hazard ratio [HR] 1·45, 95% CI 1·07-1·96, p=0·16) but no overall survival benefit (HR 1·23, 0·87-1·72, p=0·24). We saw no progression-free survival or overall survival benefit for gross total resection compared with near-total resection (HR 1·05, 0·71-1·53, p=0·8158 for progression-free survival and HR 1·14, 0·75-1·72, p=0·55 for overall survival). No significant survival benefit existed for greater extent of resection for patients with WNT, SHH, or group 3 tumours (HR 1·03, 0·67-1·58, p=0·89 for sub-total resection vs gross total resection). For patients with group 4 tumours, gross total resection conferred a benefit to progression-free survival compared with sub-total resection (HR 1·97, 1·22-3·17, p=0·0056), especially for those with metastatic disease (HR 2·22, 1·00-4·93, p=0·050). However, gross total resection had no effect on overall survival compared with sub-total resection in patients with group 4 tumours (HR 1·67, 0·93-2·99, p=0·084).; Interpretation: The prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. Although maximum safe surgical resection should remain the standard of care, surgical removal of small residual portions of medulloblastoma is not recommended when the likelihood of neurological morbidity is high because there is no definitive benefit to gross total resection compared with near-total resection.; Funding: Canadian Cancer Society Research Institute, Terry Fox Research Institute, Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, and the Garron Family Chair in Childhood Cancer Research. (Copyright © 2016 lsevier Ltd. All rights reserved.)J Clin Oncol. 1999 Mar;17(3):832-45. (PMID: 10071274); J Neurooncol. 2009 Aug;94(1):51-6. (PMID: 19184579); J Neurosurg. 1990 Apr;72(4):572-82. (PMID: 2319316); PLoS One. 2012;7(4):e33415. (PMID: 22485143); Eur J Cancer. 1990 Apr;26(4):464-9. (PMID: 2141512); J Clin Oncol. 2014 Jun 10;32(17):1760-8. (PMID: 24516024); Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):106-12. (PMID: 19695790); Cancer Genet. 2011 Nov;204(11):577-88. (PMID: 22200083); Acta Neuropathol. 2012 Apr;123(4):615-26. (PMID: 22057785); J Clin Oncol. 2014 Mar 20;32(9):886-96. (PMID: 24493713); Clin Cancer Res. 2009 Apr 1;15(7):2463-71. (PMID: 19276247); Acta Neuropathol. 2012 Apr;123(4):465-72. (PMID: 22134537); Pediatr Blood Cancer. 2014 Jul;61(7):1190-4. (PMID: 24616042); Pediatr Neurosurg. 1994;20(1):19-29. (PMID: 8142278); Neurosurgery. 1996 Feb;38(2):265-71. (PMID: 8869053); J Clin Oncol. 2006 Sep 1;24(25):4202-8. (PMID: 16943538); J Clin Oncol. 2010 Nov 20;28(33):4961-8. (PMID: 20940197); J Neurooncol. 2008 Oct;90(1):99-103. (PMID: 18566744); J Clin Oncol. 2006 Apr 20;24(12):1924-31. (PMID: 16567768); Nat Rev Cancer. 2012 Dec;12(12):818-34. (PMID: 23175120); Brain. 2000 May;123 ( Pt 5):1041-50. (PMID: 10775548); J Clin Oncol. 2013 Aug 10;31(23):2936-41. (PMID: 23857975); Neurosurgery. 1995 Nov;37(5):885-93. (PMID: 8559336); Expert Rev Neurother. 2012 Jul;12(7):871-84. (PMID: 22853794); J Clin Oncol. 2011 Apr 10;29(11):1408-14. (PMID: 20823417); J Neurosurg. 2006 Dec;105(6 Suppl):444-51. (PMID: 17184075); Acta Neuropathol. 2013 Mar;125(3):373-84. (PMID: 23184418); Lancet Oncol. 2006 Oct;7(10):813-20. (PMID: 17012043); Neuro Oncol. 2016 Feb;18(2):291-7. (PMID: 25605817); Neurosurgery. 2000 Oct;47(4):879-85; discussion 885-7. (PMID: 11014428); Pediatr Neurosurg. 1996 Oct;25(4):182-7. (PMID: 9293545); AJNR Am J Neuroradiol. 2014 Jul;35(7):1263-9. (PMID: 24831600); Acta Neuropathol. 2014 Jul;128(1):137-49. (PMID: 24791927); Lancet Oncol. 2013 Nov;14(12):1200-7. (PMID: 24140199); Nat Rev Neurol. 2012 May 08;8(6):340-51. (PMID: 22565209); J Clin Oncol. 2001 Jan 15;19(2):480-7. (PMID: 11208842); Acta Neuropathol. 2012 Apr;123(4):473-84. (PMID: 22358457); J Clin Oncol. 2012 Sep 10;30(26):3187-93. (PMID: 22851561); J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6. (PMID: 11878577). Linking ISSN: 14702045. Subset: MEDLINE; Grant Information: P50 CA190991 United States CA NCI NIH HHS; R01 CA159859 United States CA NCI NIH HHS; Canada CIHR; R01 NS096236 United States NS NINDS NIH HHS; R01 CA163737 United States CA NCI NIH HHS; R01 CA148621 United States CA NCI NIH HHS; R01 CA148699 United States CA NCI NIH HHS; F31 CA203372 United States CA NCI NIH HHS; R01 CA163722 United States CA NCI NIH HHS Date of Electronic Publication: 2016 Mar 12. ; Original Imprints: Publication: London : Lancet Pub. Group, c2000- <br />